IL316772A - Dose transmitters containing complement factor I for the treatment of eye diseases - Google Patents

Dose transmitters containing complement factor I for the treatment of eye diseases

Info

Publication number
IL316772A
IL316772A IL316772A IL31677224A IL316772A IL 316772 A IL316772 A IL 316772A IL 316772 A IL316772 A IL 316772A IL 31677224 A IL31677224 A IL 31677224A IL 316772 A IL316772 A IL 316772A
Authority
IL
Israel
Prior art keywords
cfi
per eye
weeks
seq
amino acid
Prior art date
Application number
IL316772A
Other languages
English (en)
Hebrew (he)
Inventor
Grant E Blouse
Moan Natacha Le
Tom Knudsen
Original Assignee
Vertex Pharma
Grant E Blouse
Moan Natacha Le
Tom Knudsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma, Grant E Blouse, Moan Natacha Le, Tom Knudsen filed Critical Vertex Pharma
Publication of IL316772A publication Critical patent/IL316772A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
IL316772A 2022-05-04 2023-05-04 Dose transmitters containing complement factor I for the treatment of eye diseases IL316772A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263338392P 2022-05-04 2022-05-04
PCT/US2023/066620 WO2023215840A1 (en) 2022-05-04 2023-05-04 Complement factor i dosing regimens for treating ocular diseases

Publications (1)

Publication Number Publication Date
IL316772A true IL316772A (en) 2025-01-01

Family

ID=86760162

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316772A IL316772A (en) 2022-05-04 2023-05-04 Dose transmitters containing complement factor I for the treatment of eye diseases

Country Status (10)

Country Link
US (1) US20250177482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515091A (cg-RX-API-DMAC7.html)
KR (1) KR20250008764A (cg-RX-API-DMAC7.html)
CN (1) CN119698286A (cg-RX-API-DMAC7.html)
AU (1) AU2023265150A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251504A1 (cg-RX-API-DMAC7.html)
IL (1) IL316772A (cg-RX-API-DMAC7.html)
TW (1) TW202400627A (cg-RX-API-DMAC7.html)
WO (1) WO2023215840A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117551A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2021257480A2 (en) * 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods

Also Published As

Publication number Publication date
KR20250008764A (ko) 2025-01-15
JP2025515091A (ja) 2025-05-13
AU2023265150A1 (en) 2024-11-14
CA3251504A1 (en) 2023-11-09
CN119698286A (zh) 2025-03-25
WO2023215840A1 (en) 2023-11-09
EP4518881A1 (en) 2025-03-12
US20250177482A1 (en) 2025-06-05
TW202400627A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
IL299048A (en) Variants of complement factor - 1 fusion structures and preparations containing them and their uses
IL287019B1 (en) Compositions and methods for internalizing enzymes
IL262060B (en) A method for selecting recombinant proteins with a high amount of mannose-6-phosphate
IL322464A (en) Methods and compositions for administering therapeutic protein
IL271193B2 (en) Preparations and methods for internalizing enzymes
IL302720A (en) GDF15 fusion proteins and their uses
US20140186326A1 (en) Modified acid alpha glucosidase with accelerated processing
IL282987B2 (en) Delivery constructs for transcytosis and related methods
EP4031117B1 (en) Ngf mutant for use in treatment or prevention of ophthalmic disorders
IL270503B2 (en) Depletion of homocysteine by human enzymes for the treatment of patients with hyperhomocysteinemia and homocystinuria
KR20240000391A (ko) N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
IL262044A (en) Conjugated c1 esterase inhibitor and uses thereof
US20250011379A1 (en) Complement factor i-related compositions and methods
IL268971B2 (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
CN108291246A (zh) 修饰的溶酶体蛋白及其产生
US20250177482A1 (en) Complement factor i dosing regimens for treating ocular diseases
EP4260871A1 (en) Optical nerve protecting agent containing anti-lrp1 antibody
IL305246A (en) Mutated arylsulfatase a with increased stability
WO2025053776A1 (ru) Антитела против рецептора трансферрина и их применение
IL313777A (en) Complement factor-i formulations
Cendales Structure and function studies of recombinant clusterin